Chester County News and Community Website
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) this week announced the completion of dosing in the third cohort of its Phase 1/2 ArMaDa clinical trial for OCU410, a novel gene …
Ocugen Completes Dosing in Phase 1/2 Trial for Gene Therapy to Treat Geographic Atrophy Read More
PHILADELPHIA, PA — Vittoria Biotherapeutics announced a significant publication by University of Pennsylvania investigators in Science Immunology. The paper highlights the role of CD5, an immunomodulatory protein, in enhancing engineered …
Vittoria Biotherapeutics’ Senza5 Platform Featured in Science Immunology Read More
HORSHAM, PA — STRATA Skin Sciences, Inc. (NASDAQ: SSKN) has announced the publication of a clinical study highlighting the effectiveness of its TheraClear®X Acne Therapy System. The study, titled “Advancing …
STRATA Skin Sciences Publishes Promising Acne Therapy Study Read More
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has received approval from the U.S. Food and Drug Administration (FDA) to transition to a new solid form of buntanetap in future …
Annovis Bio Gains FDA Approval for New Form of Neurodegenerative Drug Read More
BERWYN, PA — Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) recently announced positive results from a pilot study using a swine model for Probudur, its long-acting pain relief drug. Probudur, a liposomal …
Virpax Pharmaceuticals Reports Promising Results for Pain Relief Drug Read More
WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) has announced a collaboration with Merck to evaluate a new cancer treatment. The Phase 2 clinical trial will test Prelude’s investigational drug, …
Prelude Therapeutics Joins Forces with Merck for Cancer Treatment Trial Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) recently disclosed the encouraging results of its Phase III clinical trial related to Parkinson’s disease treatment. The experimental drug, buntanetap, has shown …
Annovis Bio’s Breakthrough in Parkinson’s Treatment: New Drug Buntanetap Shows Promise Read More
PLYMOUTH MEETING, PA — Braeburn Inc. has announced the recent tpublication of a post hoc analysis in JAMA Network Open, revealing promising results for its drug BRIXADI in the fight …
Braeburn’s BRIXADI Shows Promise Against Fentanyl in Opioid Use Disorder Study Read More
KING OF PRUSSIA, PA, and CARY, NC — United BioSource LLC (UBC) and Thread® recently announced the expansion of their SitePlus solution. This joint offering, born from a six-year collaboration, …
United BioSource and Thread Expand Research Solution to Boost Clinical Trial Efficiency Read More
PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its innovative cancer treatment, CT-0525. This therapy targets …
FDA Grants Fast Track Status to Carisma Therapeutics’ New Cancer Therapy Read More